Clinical trial NCT03789721: Adrenoleukodystrophy National Registry Study
Official title: Adrenoleukodystrophy National Registry Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: ALD (Adrenoleukodystrophy)
Adrenoleukodystrophy
Cerebral Adrenoleukodystrophy
Keywords: Registry, VLCFA, ABCD1, X-chromosome
Lead sponsor: Masonic Cancer Center, University of Minnesota
Sponsor class: OTHER
First posted: 2018-12-31
Enrollment: 1000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: participants with Adrenoleukodystrophy (ALD) and known/presumed mutation for ALD.

Brief summary: The aim of this registry to understand the natural history and disease progression in ALD and potentially develop bio-markers using the biospecimens collected using this registry.

Detailed description: This is a prospective, non-therapeutic protocol designed to create and maintain a registry of participants with Adrenoleukodystrophy (ALD) and known/presumed mutation for ALD. This study also involves maintaining a prospective biorepository to collect and store buccal swab, blood, stool and urine samples as well. In this protocol, pediatric (including infants), adolescents and adult patients with confirmed or presumed ALD (based on positive VLCFA testing and/or confirmed mutation) will be offered potential study participation. Additionally, presumed mutation for ALD (based on pedigree or confirmed mutation) will be offered potential study participation. After appropriate consent (online or in-person), subjects will be requested to provide a medical history (with authorization of release of medical records), longitudinal biospecimens, and permission to perform laboratory analyses on these samples. The overall goal is to understand the natural disease course in affected and unaffected patients (identified patients and relatives with a diagnosis of ALD), as well as women with ALD to assemble a resource of clinical, medical, and biological data from the participants. This study also aims to understand the outcomes of this disease, as well as possibly develop biomarkers to identify prognostic markers for disease progression, which may help develop effective interventions. The biospecimen bank and registry will provide access to samples and data for the ongoing studies as well as will provide an important resource for the future research.

Eligibility criteria: Inclusion Criteria

* Age 0 - 100
* ALD patients or family member meeting any of the following criteria:

  * Any patient diagnosed with ALD (confirmed by positive VLCFA testing and/or genetic mutation).
  * Known or presumed mutation with ALD based on pedigree or confirmed mutation in ABCD1 gene
* Participants living in the United States and territories

Exclusion Criteria

* Patients diagnosed with ALD who lack the capacity to consent/assent AND do not have a designated legally authorized representative or guardian.
* Patients who have undergone BMT or other cellular therapy .
* Patients not fluent in English who are unable to consent in-person at the BMT Journey Clinic.
* Patients who are illiterate
* Patient determined by the PI or designee to be unlikely to complete required study components (due to language barriers, compliance issues, etc.)

Primary outcomes:
measure: Collect Clinical and Epidemiological Data
timeFrame: 10 Years
Secondary outcomes:
Other outcomes:
Locations:
city: Minneapolis
country: United States
facility: Masonic Cancer Center at University of Minnesota
state: Minnesota
Study officials:
References: